Catalyst Event
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (6990) · Other
From Akros SCHK HK-U.S. Tech 100 Index (ASHUSTC)
5/13/2026, 12:00:00 AM
The company is expected to receive Investigational New Drug (IND) approval from China's NMPA for SKB118; this pipeline milestone is estimated to have a 5% price impact as it validates the drug's potential expected.
Korean Translation
진행성 고형암 치료를 위한 SKB118의 임상시험계획(IND) 승인 획득이 예상되며, 이는 파이프라인 가치 제고로 인해 약 5%의 주가 영향이 예상됨.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
Microsoft Corp (MSFT) · Earnings Release
Microsoft is scheduled to report its Q4 and full-year fiscal 2026 earnings results on 2026-07-28, with analysts forecasting EPS around $4.24-$4.33. High importance is estimated due to typical 10% price volatility following earnings scheduled.
7/28/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Other
AMD's 'Advancing AI 2026' event to detail future AI product roadmaps on July 23, 2026 is expected to have a 5% price impact scheduled.
7/23/2026, 12:00:00 AM
Amphenol Corp (APH) · Earnings Release
Next quarterly earnings release for Q2 2026 is a routine administrative event with low expected impact, scheduled.
7/22/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Earnings Release
Q2 2026 earnings release scheduled for 2026-07-22; low importance estimated as earnings typically cause moderate volatility, expected.
7/22/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM